 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- [225Ac]-FPI-2068 / AstraZeneca
A Phase 1, First-in-human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors (Exhibit Hall D - Science Pavilion (Convention Center); Screen 56; In-Person Only) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1072;
P1
[225Ac]-FPI-2068 is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has been shown to have promising efficacy in a range of preclinical tumor models. This is a Trial in Progress.
- || [225Ac]-FPI-2068 / AstraZeneca
Trial initiation date, Metastases: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours (clinicaltrials.gov) - Apr 19, 2024
P1, N=110, Recruiting, Sponsor: Fusion Pharmaceuticals Inc.
This is a Trial in Progress. Initiation date: Feb 2024 --> Jun 2024
- ||| [225Ac]-FPI-2068 / AstraZeneca
Enrollment open, Metastases: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours (clinicaltrials.gov) - Jan 11, 2024
P1, N=110, Recruiting, Sponsor: Fusion Pharmaceuticals Inc.
Initiation date: Feb 2024 --> Jun 2024 Not yet recruiting --> Recruiting
- ||| [225Ac]-FPI-2068 / AstraZeneca
New P1 trial, Metastases: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours (clinicaltrials.gov) - Nov 27, 2023
P1, N=110, Not yet recruiting, Sponsor: Fusion Pharmaceuticals Inc.
- FPI-2068 / AstraZeneca, Fusion Pharma
FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_299;